Paper36969187
Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment.
Surendran A and 28 others. Front Immunol, 2023. Cited by 13 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment. Papers, record 36969187. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36969187
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Fatty acid transport protein inhibition sensitizes breast and ovarian cancers to oncolytic virus therapy via lipid modulation of the tumor microenvironment.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Oncolytic Virotherapy | Major topic |
| Oncolytic Viruses | Major topic |
| Ovarian Neoplasms | Major topic |
| Humans | |
| Female | |
| Tumor Microenvironment | |
| Culture Media, Conditioned | |
| Lipids |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 377104 | CIHR | Canada | PubMed |
Source PubMed
References72
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 30,996,346 | Fatty acid transport protein 2 reprograms neutrophils in cancer. | Nature | 2019 | https://conductscience.org/library/papers/30996346 | PubMed |
| 2 | 22,883,233 | IRE1α induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. | Cell Metab | 2012 | https://conductscience.org/library/papers/22883233 | PubMed |
| 3 | 29,540,614 | Obesity promotes resistance to anti-VEGF therapy in breast cancer by up-regulating IL-6 and potentially FGF-2. | Sci Transl Med | 2018 | https://conductscience.org/library/papers/29540614 | PubMed |
| 4 | 26,499,941 | Interaction Between Breast Cancer Cells and Adipose Tissue Cells Derived from Fat Grafting. | Aesthet Surg J | 2016 | https://conductscience.org/library/papers/26499941 | PubMed |
| 5 | 32,958,389 | Redirecting oncolytic viruses: Engineering opportunists to take control of the tumour microenvironment. | Cytokine Growth Factor Rev | 2020 | https://conductscience.org/library/papers/32958389 | PubMed |
| 6 | 32,499,221 | Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. | Cancer Discov | 2020 | https://conductscience.org/library/papers/32499221 | PubMed |
| 7 | 30,049,987 | Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/30049987 | PubMed |
| 8 | 26,394,026 | Chemical inhibition of fatty acid absorption and cellular uptake limits lipotoxic cell death. | Biochem Pharmacol | 2015 | https://conductscience.org/library/papers/26394026 | PubMed |
| 9 | 32,660,751 | Mechanisms of measles virus oncolytic immunotherapy. | Cytokine Growth Factor Rev | 2020 | https://conductscience.org/library/papers/32660751 | PubMed |
| 10 | 23,332,453 | Adipose tissue attracts and protects acute lymphoblastic leukemia cells from chemotherapy. | Leuk Res | 2013 | https://conductscience.org/library/papers/23332453 | PubMed |
| 11 | 8,113,756 | Lauric acid inhibits the maturation of vesicular stomatitis virus. | J Gen Virol | 1994 | https://conductscience.org/library/papers/8113756 | PubMed |
| 12 | 29,925,665 | APOBEC3G-Regulated Host Factors Interfere with Measles Virus Replication: Role of REDD1 and Mammalian TORC1 Inhibition. | J Virol | 2018 | https://conductscience.org/library/papers/29925665 | PubMed |
| 13 | 25,894,825 | Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. | Nat Med | 2015 | https://conductscience.org/library/papers/25894825 | PubMed |
| 14 | 28,362,167 | Adipocyte Secretome Increases Radioresistance of Malignant Melanocytes by Improving Cell Survival and Decreasing Oxidative Status. | Radiat Res | 2017 | https://conductscience.org/library/papers/28362167 | PubMed |
| 15 | 35,155,561 | Over-Expression and Prognostic Significance of FATP5, as a New Biomarker, in Colorectal Carcinoma. | Front Mol Biosci | 2021 | https://conductscience.org/library/papers/35155561 | PubMed |
| 16 | 24,453,963 | From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer. | PLoS Pathog | 2014 | https://conductscience.org/library/papers/24453963 | PubMed |
| 17 | 30,728,288 | Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. | Sci Transl Med | 2019 | https://conductscience.org/library/papers/30728288 | PubMed |
| 18 | 24,672,774 | A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population. | Front Oncol | 2014 | https://conductscience.org/library/papers/24672774 | PubMed |
| 19 | 30,626,434 | Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics. | J Immunother Cancer | 2019 | https://conductscience.org/library/papers/30626434 | PubMed |
| 20 | 23,500,888 | Adipose tissue and adipocytes support tumorigenesis and metastasis. | Biochim Biophys Acta | 2013 | https://conductscience.org/library/papers/23500888 | PubMed |
Cited by9
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 13 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,798,757 | Lipid metabolism reprogramming: key mechanism of breast cancer endocrine therapy resistance. | Front Oncol | 2026 | https://conductscience.org/library/papers/42798757 | PubMed |
| 41,668,072 | Exploiting synthetic lethality in epithelial ovarian cancer: multi-dimensional approaches beyond DNA damage repair. | Mol Cancer | 2026 | https://conductscience.org/library/papers/41668072 | PubMed |
| 41,470,247 | Targeting Ovarian Neoplasms: Subtypes and Therapeutic Options. | Medicina (Kaunas) | 2025 | https://conductscience.org/library/papers/41470247 | PubMed |
| 40,709,184 | Crosstalk between stromal, immune, and ovarian cancer cells in lipid-rich tumor microenvironment exhibits proliferative features. | Front Immunol | 2025 | https://conductscience.org/library/papers/40709184 | PubMed |
| 40,647,532 | Immunohistological Examination of HEATR1 and SLC27A2 Expression in ccRCC Samples to Evaluate Their Potential as Prognostic Markers-A Preliminary Study. | Cancers (Basel) | 2025 | https://conductscience.org/library/papers/40647532 | PubMed |
| 39,861,805 | Employing the Oncolytic Vesicular Stomatitis Virus in Cancer Virotherapy: Resistance and Clinical Considerations. | Viruses | 2024 | https://conductscience.org/library/papers/39861805 | PubMed |
| 39,125,923 | The Role of Adipocytes Recruited as Part of Tumor Microenvironment in Promoting Colorectal Cancer Metastases. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/39125923 | PubMed |
| 39,113,876 | Cancer-associated adipocytes in the ovarian cancer microenvironment. | Am J Cancer Res | 2024 | https://conductscience.org/library/papers/39113876 | PubMed |
| 37,753,372 | SARS-CoV-2 infection as a potential risk factor for the development of cancer. | Front Mol Biosci | 2023 | https://conductscience.org/library/papers/37753372 | PubMed |
Genes21
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/36969187
GET https://conductscience.org/api/papers/v1/36969187/authors?page=2